Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An instance of Creutzfeldt Jacob disease that is acquired during the lifetime of the individual.
Biomarker and diagnostic research for acquired Creutzfeldt-Jakob disease has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for acquired Creutzfeldt-Jakob disease.
48 publications have been identified in PubMed for acquired Creutzfeldt-Jakob disease. Research spans Case Report / Case Series (58%), Review / Meta-Analysis (13%), and Diagnostic / Biomarker (10%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 28 | 58% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 11:32 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acquired Creutzfeldt-Jakob disease
Research summaries
6 |
13% |
Testing and diagnosis research | 5 | 10% |
Laboratory research | 5 | 10% |
Disease patterns and progression | 4 | 8% |
Bilavu R (2026). [PMID: 41548514](https://pubmed.ncbi.nlm.nih.gov/41548514/). *J Neuroimmunol*. [Review / Meta-Analysis]
Zhu Z (2026). [PMID: 41623402](https://pubmed.ncbi.nlm.nih.gov/41623402/). *BMJ Neurol Open*. [Case Report / Case Series]
Myskiw J (2026). [PMID: 41586487](https://pubmed.ncbi.nlm.nih.gov/41586487/). *Ann Neurol*. [Diagnostic / Biomarker]
Jarquín-Rios VR (2026). [PMID: 41384000](https://pubmed.ncbi.nlm.nih.gov/41384000/). *Med Int (Lond)*. [Case Report / Case Series]
Skáčik P (2026). [PMID: 41973065](https://pubmed.ncbi.nlm.nih.gov/41973065/). *Cent Eur J Public Health*. [Case Report / Case Series]
Esezoobo O (2026). [PMID: 41694929](https://pubmed.ncbi.nlm.nih.gov/41694929/). *Cureus*. [Case Report / Case Series]
Tahara D (2026). [PMID: 41762037](https://pubmed.ncbi.nlm.nih.gov/41762037/). *Prion*. [Case Report / Case Series]
Li CJ (2026). [PMID: 42125878](https://pubmed.ncbi.nlm.nih.gov/42125878/). *Ann Clin Transl Neurol*. [Case Report / Case Series]
Balash Y (2026). [PMID: 41785192](https://pubmed.ncbi.nlm.nih.gov/41785192/). *Dement Geriatr Cogn Disord*. [Diagnostic / Biomarker]
Eraña H (2026). [PMID: 41663312](https://pubmed.ncbi.nlm.nih.gov/41663312/). *Brain Pathol*. [Basic Science / Preclinical]
AI-curated news mentioning acquired Creutzfeldt-Jakob disease
Updated Sep 15, 2026
A recent publication discusses the advancements in diagnostic methods for Creutzfeldt-Jakob disease, highlighting the contrast with the lack of effective therapies. The article emphasizes the need for continued research to bridge the gap between diagnosis and treatment.
A new case report on sporadic Creutzfeldt-Jakob disease has been published, contributing to the understanding of this rare neurodegenerative disorder. The findings may provide insights into disease mechanisms and potential therapeutic approaches.
A recent study highlights a case of genetic Creutzfeldt-Jakob disease linked to a 5-octapeptide repeat insertion in the PRNP gene. This research contributes to the understanding of the genetic factors involved in this rare neurodegenerative disorder.
The Senate has introduced resolution SRES 499 to support the goals of 'Creutzfeldt-Jakob Disease Awareness Day.' This resolution has been referred to the Committee on Health, Education, Labor, and Pensions for further consideration.
The House has referred HRES 872, which supports the goals of 'Creutzfeldt-Jakob Disease Awareness Day,' to the Committee on Energy and Commerce. This resolution aims to raise awareness about CJD, a rare and fatal neurodegenerative disorder.